Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse - Wikidata - wikimedia - TriplyDB

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

http://www.wikidata.org/entity/Q35022217

about

B-Raf and the inhibitors: from bench to bedside Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Use of high frequency ultrasound to monitor cervical lymph node alterations in mice Integrated genomic characterization of papillary thyroid carcinoma Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.Combined MEK and Pi3'-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo.Molecular pathogenesis and mechanisms of thyroid cancer Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells.Modulation of sodium iodide symporter in thyroid cancer Modeling follicular thyroid cancer for future therapies BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.Mouse models of follicular and papillary thyroid cancer progression.Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.Mouse models of thyroid cancer: A 2015 update.Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer Genetics and epigenetics of sporadic thyroid cancer.Overview of Genetically Engineered Mouse Models of Papillary and Anaplastic Thyroid Cancers: Enabling Translational Biology for Patient Care Improvement.Rethinking the role of oncogenes in papillary thyroid cancer initiation.MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.BRAFV600E mutation and papillary thyroid cancer: chicken or egg?Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors.Structural alterations in tumor-draining lymph nodes before papillary thyroid carcinoma metastasis.A mouse model with tamoxifen-inducible thyrocyte-specific cre recombinase activity.TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.Endocrine Disorders The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model Mouse models of sporadic thyroid cancer derived from BRAFV600E alone or in combination with PTEN haploinsufficiency under physiologic TSH levels

P2860

Q21198860-0B77011D-2532-474C-AE0D-C3AC38358F86 Q27026323-6798EDA1-1B91-4874-950C-0C9008F2DFC4 Q27322837-A53B5050-5903-4018-8810-67B019A0BE50 Q28251986-8E5FC0A8-8474-43D9-990A-C288A46C8429 Q33558907-42AC7E22-CEC4-4256-AD6B-9C386BDB9313 Q33648582-AA40DC59-6AD5-4C23-9B47-08D015251B12 Q34329018-9B3CC5BB-C2AB-4A96-AE9B-055B75F245B8 Q34571096-89D323DA-4674-4F15-9F7E-2DED1AAF4F1F Q35578577-336635DD-D4BA-40AC-AF86-C341E7199B8D Q35598807-8DA0B43A-363F-4F5B-95BF-D3BCB644ABBC Q35690173-BCF8E225-81C1-4B8B-9E09-1586ACBC9F8E Q35832908-4DD7ABAA-B439-4D62-89B3-2F9014FB2B71 Q35857363-FD8CF4B1-E413-466C-A4AB-E67ADA2D6274 Q35908104-92418C9C-EF4C-4A5C-A81B-8F010ECBCC36 Q35914464-D6A1106F-CD20-418A-BB46-8B9C67CDBD6C Q35920997-712A5A8C-F633-4DEF-BBFB-0B60B5842221 Q35971896-4FDEDB62-8D6D-4809-955E-A34963935185 Q36001219-15170A02-4D23-45B7-A84B-15F147021868 Q36255616-0A1C5FD0-501F-466D-9B3C-A9FE541BA254 Q36405539-0910D31A-710D-4641-84DB-34B2FE8C6643 Q37376300-07DD778B-194E-4D14-B9E6-B0C7809F1B17 Q37384015-A3B8550E-D752-4E09-971D-0D3D0D692656 Q37666383-D0F40A3C-1286-4CF2-85AF-9B34EBC5BB85 Q37680195-B7DFACD6-86F2-4CF1-8A61-BB1FC53CDD58 Q37712700-6634FAC4-B8A5-4169-90FB-F460DE4946D2 Q37725293-6D6C5EAE-B142-4055-963D-EA8BA428220B Q38128097-6EC9FCFA-2E69-4CC7-BF11-B8B510D200E9 Q38581928-DB8F5866-C5FB-4B12-A2E1-1EBC41617CE6 Q41878891-B74EC2EE-A488-480F-9137-70CAFB7C3BA3 Q42019758-8B91D13F-50FF-49B2-8758-753B8E03F8C2 Q42707282-24272845-FDF6-4ADB-BCE2-A5360E549286 Q46636066-4232EF33-73C8-4C53-A672-786547E38CC7 Q47142625-CEBFC88E-EAFE-4F58-987D-EA2AFEB9AEAA Q47149651-1A0328E2-5AA2-4A3C-8315-E0E933AAF46C Q51170449-34F9E1A5-4148-4630-8C45-ACD41507ED27 Q52664598-39FD3C34-DAE0-45F5-B06E-2BE407B60919 Q53439139-BABAF7F1-DAB3-4932-A322-E387B23401B4 Q57765055-86E36FFA-6BDA-4D6B-BF08-D5B5AFD0353A Q58706948-4FEC6F8F-7406-43D4-9F62-17928E8F47AA Q58797975-44012DED-EEB5-44B7-A78C-DAAED06804E1

P2860

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

http://www.wikidata.org/entity/Q35022217

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

@ast

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

@en

type

label

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

@ast

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

@en

prefLabel

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

@ast

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

@en

P1433

Q35022217-6416886A-E528-4B84-8A4E-A6C0982B8607

P1476

Q35022217-A2056A0D-278D-465B-A762-4E6A9E84F086

P2093

Q35022217-0D34F7C8-1157-40FD-BAB7-25151CFBF188

Q35022217-2065FA6D-319F-4CD3-838F-0EFF71EC01F8

Q35022217-76C3BAC5-ACB5-41C4-ACDF-976E2C0B7CB7

P2860

Q35022217-0171F464-1942-4A47-8C2B-B5A422D1D988

Q35022217-0F421C7C-F21E-4322-9EAD-81892AC282FD

Q35022217-2D8FE11F-083D-4911-A5B0-48898B07EE44

Q35022217-35084987-012B-48E0-A280-CDED549767BD

Q35022217-39E63724-F6D1-49DF-9A70-3F789B2AEF40

Q35022217-3AA26993-2660-47C8-84C0-67EA615EBD82

Q35022217-5178496B-3D07-4140-A63D-E7858A7EDFEC

Q35022217-557EF09F-CBD2-4991-876C-7F4A68D84865

Q35022217-5AC1FFAD-4BC9-45A5-BA1B-F39C16381135

Q35022217-6673B532-F18D-48E3-8E88-C269CDCF9D80

P304

Q35022217-89443562-27DC-46F1-998E-F683A1CD6819

P31

Q35022217-7DE3BCA4-4A76-4F7D-83FE-FACDB10FC118

P356

Q35022217-A0DA06E9-4E94-461F-8861-6A04CA6144F7

P407

Q35022217-6EA978E5-2467-43B5-8804-D1BA5289A330

P433

Q35022217-B67895FB-ADFA-41B6-B560-24F39D55C8B2

P478

Q35022217-6B12AD93-FBD5-4674-BFA4-CA6DD19ABA05

P50

Q35022217-4F78557E-8D3C-43D7-9EC5-62EFB6D6F40F

Q35022217-A64049A7-CA4D-4863-94B7-081D0FFCE6EF

P577

Q35022217-3E673B4E-DE6D-48D8-91EC-FC5E7C2A1CA4

P698

Q35022217-8DA20564-39FF-4286-A916-6CDE4E21181F

P932

Q35022217-64AF1978-6A84-4C85-8A2A-52B327CAA1B0

P356

0008-5472.CAN-10-4463

P1433

Cancer Research

P1476

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

@en

P2093

Elena Amendola

http://www.w3.org/2001/XMLSchema#string

Gioia Iezza

http://www.w3.org/2001/XMLSchema#string

Martin McMahon

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

The Immunocytochemistry Is a Valuable Tool in the Diagnosis of Papillary Thyroid Cancer in FNA's Using Liquid-Based Cytology

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.

Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo

Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.

BRAF mutation in thyroid cancer.

The use of targeted mouse models for preclinical testing of novel cancer therapeutics.

Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.

P304

3863-3871

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-4463

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Roch-Philippe Charles

P577

2011-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21512141

http://www.w3.org/2001/XMLSchema#string

P932

3107361

http://www.w3.org/2001/XMLSchema#string